{"preliminary_commentary":{"by_channel":{"x_thread":12,"youtube":5,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06132113\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"DAREON-7","nct_id":"NCT06132113","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dareon-7-nct06132113. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Part A1: BI 764532 low dose + carboplatin + etoposide","type":"EXPERIMENTAL"},{"description":null,"label":"Part A1: BI 764532 medium dose + carboplatin + etoposide","type":"EXPERIMENTAL"},{"description":null,"label":"Part A1: BI 764532 high dose + carboplatin + etoposide","type":"EXPERIMENTAL"},{"description":null,"label":"Part B: BI 764532 + carboplatin + etoposide","type":"EXPERIMENTAL"},{"description":null,"label":"Part B: BI 764532 + cisplatin + etoposide","type":"EXPERIMENTAL"},{"description":null,"label":"Part A2: BI 764532 + carboplatin + etoposide","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Neuroendocrine Neoplasms"],"enrollment":{"count":65,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"BI 764532","otherNames":["Obrixtamig"],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Etoposide","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"Boehringer Ingelheim","official_title":"DAREON™-7: A Phase I, Open-label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-line Treatment of Patients With Neuroendocrine Carcinomas (NEC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-10-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part A1: Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period","timeFrame":"Up to 21 days."},{"measure":"Part B: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment period","timeFrame":"Up to 36 months."},{"measure":"Part A2: Reduced monitoring: the occurrence of DLTs during the on-treatment period","timeFrame":"Up to 36 months."}],"references":[],"start_date":{"date":"2024-01-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers","url":"https://clinicaltrials.gov/study/NCT06132113"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dareon-7-nct06132113"}